Association of Angiotensin II Receptor Type 1 and Endothelin-1 Receptor Type A Agonistic Autoantibodies With Adverse Remodeling and Cardiovascular Events After Acute Myocardial Infarction

被引:1
|
作者
Tona, Francesco [1 ]
Civieri, Giovanni [1 ]
Vadori, Marta [1 ]
Masiero, Giulia [1 ]
Iop, Laura [1 ]
Marra, Martina Perazzolo [1 ]
Perin, Valentina [1 ]
Cuciz, Elisa [1 ]
Cecere, Annagrazia [1 ]
Bernava, Giacomo [1 ]
Tansella, Donatella [1 ]
Naumova, Nataliia [1 ]
Grewal, Simran [2 ]
Cozzi, Emanuele [1 ]
Iliceto, Sabino [1 ]
机构
[1] Univ Padua, Dept Cardiac Thorac Vasc Sci & Publ Hlth, Via N Giustiniani 2, I-35128 Padua, PD, Italy
[2] Penn State Hershey Med Ctr, Hershey, PA USA
来源
JOURNAL OF THE AMERICAN HEART ASSOCIATION | 2024年 / 13卷 / 04期
关键词
antibodies; immunology; prognosis; remodeling; STEMI; CARDIAC-HYPERTROPHY; HEART-FAILURE; REPERFUSION; ANTIBODIES; CRITERIA; MODEL;
D O I
10.1161/JAHA.123.032672
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: The left ventricular remodeling (LVR) process has limited the effectiveness of therapies after myocardial infarction. The relationship between autoantibodies activating AT1R-AAs (angiotensin II receptor type 1-AAs) and ETAR-AAs (autoantibodies activating endothelin-1 receptor type A) with myocardial infarction has been described. Among patients with ST-segment- elevation myocardial infarction, we investigated the relationship between these autoantibodies with LVR and subsequent major adverse cardiac events. METHODS AND RESULTS: In this prospective observational study, we included 131 patients with ST-segment-elevation myocardial infarction (61 +/- 11 years of age, 112 men) treated with primary percutaneous coronary intervention. Within 48 hours of admission, 2-dimensional transthoracic echocardiography was performed, and blood samples were obtained. The seropositive threshold for AT1R-AAs and ETAR-AAs was >10 U/mL. Patients were followed up at 6 months, when repeat transthoracic echocardiography was performed. The primary end points were LVR, defined as a 20% increase in left ventricular end-diastolic volume index, and major adverse cardiac event occurrence at follow-up, defined as cardiac death, nonfatal re-myocardial infarction, and hospitalization for heart failure. Forty-one (31%) patients experienced LVR. The prevalence of AT1R-AAs and ETAR-AAs seropositivity was higher in patients with versus without LVR (39% versus 11%, P<0.001 and 37% versus 12%, P=0.001, respectively). In multivariable analysis, AT1R-AAs seropositivity was significantly associated with LVR (odds ratio [OR], 4.66; P=0.002) and represented a risk factor for subsequent major adverse cardiac events (OR, 19.6; P= 0.002). CONCLUSIONS: AT1R-AAs and ETAR-AAs are associated with LVR in patients with ST-segment- elevation myocardial infarction. AT1R-AAs are also significantly associated with recurrent major adverse cardiac events. These initial observations may set the stage for a better pathophysiological understanding of the mechanisms contributing to LVR and ST-segment- elevation myocardial infarction prognosis.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Functional Autoantibodies Against Angiotensin II Receptor Type 1 and Endothelin-1 Receptor Type A Predict Adverse Remodeling and Cardiovascular Events After Acute Myocardial Infarction
    Civieri, Giovanni
    Masiero, Giulia
    Marra, Martina Perazzolo
    Vadori, Marta
    Iop, Laura
    Cozzi, Emanuele
    Iliceto, Sabino
    Tona, Francesco
    CIRCULATION, 2023, 148
  • [2] Angiotensin-II receptor type 1 and endothelin-1 receptor type A agonistic autoantibodies in patients with STEMI: new kids on the block
    Civieri, G.
    Martini, M.
    Masiero, G.
    Schiavon, B.
    Bernava, G.
    Vadori, M.
    Iop, L.
    Marra, M. Perazzolo
    Cecere, A.
    Leoni, L.
    Cozzi, E.
    Iliceto, S.
    Tona, F.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [3] Differential Impact of Functional Autoantibodies Against Angiotensin II Receptor Type 1 and Endothelin-1 Receptor Type A on Microvascular Obstruction and Adverse Cardiovascular Events According to Infarct Size
    Civieri, Giovanni
    Martini, Marika
    Tansella, Donatella
    Bernava, Giacomo
    Masiero, Giulia
    Meynardi, Nicola
    Marra, Martina Perazzolo
    Vadori, Marta
    Iop, Laura
    Cozzi, Emanuele
    Iliceto, Sabino
    Tona, Francesco
    CIRCULATION, 2024, 150
  • [4] Functional autoantibodies against Endothelin-1 receptor type A and Angiotensin II receptor type 1 in patients with preeclampsia
    Larsen, Sara Buttrup
    Wallukat, Gerd
    Schimke, Ingoif
    Sandager, Anna
    Christensen, Therese Tvilum
    Uldbjerg, Niels
    Torring, Niels
    PREGNANCY HYPERTENSION-AN INTERNATIONAL JOURNAL OF WOMENS CARDIOVASCULAR HEALTH, 2018, 14 : 189 - 194
  • [5] Autoantibodies to the Endothelin-1 Receptor type A and the Angiotensin II Receptor type 1 in patients with pregnancy induced hypertension and Preeclampsia
    Toerring, N.
    Larsen, S. Buttrup
    Wallukat, G.
    Schimke, I.
    Sandager, A.
    Uldbjerg, N.
    JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2018, 128 : 52 - 53
  • [6] Association of Angiotensin II Type 1 Receptor Agonistic Autoantibodies With Outcomes in Patients With Acute Aortic Dissection
    Wu, Xiao-wei
    Li, Gang
    Cheng, Xiao-bin
    Wang, Min
    Wang, Liu-lin
    Wang, Hai-hao
    Yang, Jian-ye
    Hu, Xing-jian
    JAMA NETWORK OPEN, 2021, 4 (10)
  • [7] ROLE OF AGONISTIC AUTOANTIBODIES DIRECTED TO THE ANGIOTENSIN II TYPE 1 AND THE ENDOTHELIN-1 TYPE A RECEPTORS IN SYSTEMIC SCLEROSIS
    Kil, A.
    Becker, M.
    Guenther, J.
    Lessen, C.
    Dragun, D.
    Burmester, G. R.
    Riemekasten, G.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (02) : S174 - S174
  • [8] Chronic elevations in agonistic autoantibodies to the angiotensin II type I receptor during pregnancy in rats increase arterial pressure and endothelin-1
    LaMarca, Babbette
    Dechend, Ralf
    Fournier, Lillian
    Murphy, Sydney R.
    Cockrell, Kathy
    HYPERTENSION, 2008, 52 (04) : E49 - E49
  • [9] SSc-AGONISTIC AUTOANTIBODIES DIRECTED AGAINST THE ANGIOTENSIN RECEPTOR TYPE 1 AND THE ENDOTHELIN RECEPTOR TYPE A AND THEIR EFFECTS ON IMMUNE CELLS
    Guenther, J.
    Becker, M. O.
    Kill, A.
    Riemekasten, G.
    RHEUMATOLOGY, 2012, 51 : 39 - 39
  • [10] Systemic Sclerosis - Effects of Agonistic Autoantibodies Directed Against the Angiotensin Receptor Type 1 and the Endothelin Receptor Type A On Effector Cells
    Guenther, Jeannine
    Kill, Angela
    Becker, Mike O.
    Riemekasten, Gabriela
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S639 - S640